Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14063482 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL9186761 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL15075355 | 0.86 | KMT2A (0.42) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL14898384 | 0.86 | KMT2A (0.42) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL16453346 | 0.84 | HSD17B10 (0.46) | CYP2D6SRCLMNAKMT2ACHRM2 | |
| SCHEMBL22511875 | 0.82 | KMT2A (0.58) | CYP2D6LMNAMAPK1KMT2ACHRM2 | |
| SCHEMBL7431162 | 0.82 | ADRA2C (0.57) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL31369902 | 0.82 | MME (0.50) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL31370476 | 0.82 | MME (0.50) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL31688764 | 0.82 | MME (0.50) | CYP2D6SRCLMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103360263-B | Synthesis method of lercanidipine intermediates | CHONGQING SHENGHUAXI PHARMA CO | 2015-05-13 | — | — | CN | disclosed |
| CN-103360263-A | Synthesis method of lercanidipine intermediates | CHONGQING SHENGHUAXI PHARMA CO | 2013-10-23 | — | — | CN | disclosed |
| US-7427688-B2 | Production method of optically active diphenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7321055-B2 | Production method of optically active dephenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| US-20070032658-A1 | Production method of optically active dephenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-0675902-A1 | ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1994014843-A1 | ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032658-A1 | Production method of optically active dephenylalanine compounds | TYR, PAH, DDC | CYP2D6 518/4885SRC 3616/4885LMNA 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.